Join our daily newsletter At The Bell to receive exclusive market insights
- Telix Pharmaceuticals (TLX) enters a trading halt while it plans an upcoming capital raise
- Currently, there is no information about how much the company is aiming to raise or where the funds will be spent
- Company shares will be paused until Monday, January 24, or when further details about the raise is released to the market
- Telix is a late-stage radiopharmaceutical company developing a broad portfolio of diagnostic and therapeutic assets
- On the market, Telix last traded at $8.09 per share
Telix Pharmaceuticals (TLX) has entered a trading halt while it plans an upcoming capital raise.
So far, there are no details about how much the company is aiming to raise or where the funds will be spent.
Under the halt, company shares will be paused until Monday, January 24, or when further details about the raise are released to the market, whichever one comes first.
Telix is a late-stage radiopharmaceutical company developing a broad portfolio of diagnostic and therapeutic assets using Molecularly Targeted Radiation.
Last month, the company dosed its first patient with TLX250-CDx for non-muscle invasive bladder cancer (NMIBC).
TLX250-CDx is being developed to determine whether “indeterminate renal masses” are either clear cell renal cell cancer or not.
The aim of this study is to evaluate the safety, biodistribution and dosing properties of the drug in patients with NMIBC.
This study will recruit 6 patients over 12 months, and if successful, will move to therapeutic studies for targeted alpha therapy.
On the market, Telix last traded at $8.09 per share.
